GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » Cash Conversion Cycle

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Cash Conversion Cycle : 395.41 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Yichang HEC ChangJiang Pharmaceutical Co's Days Sales Outstanding for the six months ended in Dec. 2024 was 267.91.
Yichang HEC ChangJiang Pharmaceutical Co's Days Inventory for the six months ended in Dec. 2024 was 265.
Yichang HEC ChangJiang Pharmaceutical Co's Days Payable for the six months ended in Dec. 2024 was 137.5.
Therefore, Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2024 was 395.41.


Yichang HEC ChangJiang Pharmaceutical Co Cash Conversion Cycle Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co Cash Conversion Cycle Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.69 266.52 133.88 134.58 325.61

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.74 102.68 143.93 204.87 395.41

Competitive Comparison of Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle falls into.


;
;

Yichang HEC ChangJiang Pharmaceutical Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=191.6+209.05-75.04
=325.61

Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=267.91+265-137.5
=395.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yichang HEC ChangJiang Pharmaceutical Co  (HKSE:01558) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Yichang HEC ChangJiang Pharmaceutical Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Yichang HEC ChangJiang Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Its products include Kewei, Ertongshu, Xinhaining, Oumeining and Xining.
Executives
Shao Guan Xin Yu Neng Shi Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Xiang Gang Dong Yang Guang Xiao Shou You Xian Gong Si 2101 Beneficial owner
Shen Zhen Shi Dong Yang Guang Shi Ye Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Guang Dong Dong Yang Guang Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Ru Yuan Yao Zu Zi Zhi Xian Xin Jing Ke Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Ru Yuan Yao Zu Zi Zhi Xian Yu Neng Dian Zi Shi Ye You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Meilan 2201 Interest of corporation controlled by you
Hua Xiaoyi 2201 Interest of corporation controlled by you
Zhang Yushuai 2201 Interest of corporation controlled by you
Blackstone Dawn Pte. Ltd. 2101 Beneficial owner
Blackstone Tactical Opportunities Management Associates (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Inc. 2201 Interest of corporation controlled by you
Btof (dawn Feeder) (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Management Associates Iii (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Lr Associates (cayman) – Nq Ltd. 2201 Interest of corporation controlled by you

Yichang HEC ChangJiang Pharmaceutical Co Headlines

No Headlines